研发防疫药品公司有追捧 石四药(02005.HK)涨近3% 中国医疗(08225.HK)飙升2.2倍
国家卫健委公布截至午夜，内地新型冠状病毒感染肺炎续增至5,978宗，死亡人数增至132人。研发相关应对产品个别医药股今早见有追捧，石四药(02005.HK)抗病毒药物阿比多尔胶囊已准入18个省份防控疫情产品储备目录或防控药品绿色通道，另有11个省份即将按此方式完成准入工作，股价两连涨，今早高见8.4元，新造8.03元，升2.7%，成交1,253万股，涉资1亿元。
展开新型冠状病毒药品研究的中国医疗集团(08225.HK)飙升逾2倍高见0.395元，创逾年半高，现造0.36元，飙升2.2倍，成交激增至5,006万股，创近两年高，涉资1,595万元。
石四药集团公布，为新型冠状病毒感染的疫情防控工作，中国各省市开通了首批相关防控药品直接挂网采购绿色通道，或者将相关防控药品直接纳入应急采购范围。而集团抗病毒药物阿比多尔胶囊已准入18个省份防控疫情产品储备目录或防控药品绿色通道，另有11个省份即将按此方式完成准入工作。
中国医疗表示，抗击冠状病毒药品临床大数据筛选中心，新型冠状病毒感染肺炎疫情暴发，集团成立数字临床研究专项行动组，由在抗击Sars疫情中从事临床研究的宋雪梅博士牵头，与北京大学协和医学院和武汉同济大学专家筛选战胜这次疫情的药品和开展相应RWS研究。
另边厢，获药蓝局批准於内地进行ASC22对慢性乙型肝炎患者临床试验的歌礼制药(01672.HK)今天复市股价逆市飙升高见4.6元，现造4.23元，飙升42%，成交激增至3,974万股，创近年半高，涉资1.55亿元。
歌礼制药上周四公布，公司已获得药监局批准，於中国进行ASC22对慢性乙型肝炎患者的临床试验。ASC22为获苏州康宁杰瑞生物科技许可同类首创皮下注射PD-L1抗体，公司相信，由於慢性乙型肝炎病毒感染中T细胞衰竭为影响免疫耐受性重要因素，因此阻断PD-1/PD-L1路径或为改善特定T细胞功能并实现慢性乙型肝炎临床治癒的有效免疫疗法。除ASC22外，公司仍有其他三种用於治疗慢性乙型肝炎的药品或在研药物，即市售药品Pegasys及两种内部研发的临床实验前或待临床实验在研药物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
